Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective ...
Fatima Tuz Zahra, MD, discusses the methods and design of a retrospective analysis of 65 patients with acute myeloid leukemia ...
In response, Dave presents a study to be discussed at the 2024 American Society of Hematology (ASH) Annual Meeting and ...
Nobel Prize in Chemistry highlights AI-driven breakthroughs in computational protein design and structure prediction. Tools ...
Zanidatamab is now a category 2A treatment for HER2-positive biliary tract cancer in the NCCN guidelines, following its FDA ...
In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection ...
Panelist discusses how the RRMM treatment landscape has evolved significantly, with BiTEs emerging as a promising approach.
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...
Patients with multiple myeloma face a complex, decades-long treatment journey involving care coordination, insurance ...
Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from ...
Lung cancer innovations are not only extending lives but also enhancing the quality of life for patients, offering renewed ...
CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical ...